Biovail Generic Adalat May Be Sublicensed Under Pending FTC Settlement
Biovail may sublicense Elan's generic version of Bayer's Adalat CC under a pending settlement with the Federal Trade Commission
You may also be interested in...
The Federal Trade Commission consent order with Biovail regarding Tiazac voids a proposed settlement between the company and Andrx
Patent licensing deals that relate exclusively to listing in FDA's "Orange Book" will attract antitrust scrutiny, FTC Office of Policy Planning Director Ted Cruz said
Elan plans to launch its generic version of Bayer's Adalat CC through a new distributor following a settlement with the Federal Trade Commission